Quest Diagnostics Inc.
) announced a multi-year deal with
Life Technologies Corporation
). Per the deal, Quest Diagnostics can use Life Technologies' Ion
Torrent, a next-generation sequencing (NGS) platform for the
development of molecular tests.
Quest Diagnostics had signed a similar agreement with
), whereby it will be allowed to use the latter's MiSeq
sequencing and genotyping technology platform and related
reagents for molecular laboratory-developed tests.
These deals are consistent with Quest Diagnostic's aim of
becoming a global leader in diagnostic and healthcare
Next generation sequencing is a hi-tech platform designed to
perform advanced research on DNA or RNA molecules. With access to
platforms like Ion Torrent and MiSeq, Quest Diagnostics will be
in a position to develop innovative molecular tests and deliver
results speedily and accurately. Management expects to gain
momentum by focusing on diverse fields of treatment such as
different types of cancer, neurology and women's health.
Quest Diagnostics has been working on strengthening its suite
of diagnostic tests for quite some time now. In 2013, Quest
Diagnostics launched BRCAvantage to assess mutations in the BRCA1
and BRCA2 genes related to hereditary breast cancer. The company
also offers advanced testing services for myelodysplastic
In a bid to enhance its diagnostics services, Quest
Diagnostics acquired ConVerge Diagnostic Services and the
lab-related operations of Dignity Health and UMass Memorial
Medical Center in 2013. Quest Diagnostics also introduced the
Opioid Therapy Genetic Test which was aimed towards providing
effective pain relief.
Currently, Quest Diagnostics has a Zacks Rank #4 (Sell). A
better-ranked stock in the broader healthcare industry is
Almost Family Inc.
), sporting a Zacks Rank #1 (Strong Buy).
ALMOST FAMILY (AFAM): Free Stock Analysis
QUEST DIAGNOSTC (DGX): Free Stock Analysis
ILLUMINA INC (ILMN): Free Stock Analysis
LIFE TECHNOLOGS (LIFE): Free Stock Analysis
To read this article on Zacks.com click here.